Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 115 от 154

Активно (без набиране) Фаза 3

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Non-Clear Cell Renal Cell Carcinoma

This is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received prior systemic anticancer therapy.

Начало: 01.01.2023 Край: 01.06.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +22 Exelixis NCT05678673

Активно (без набиране) Фаза 3

A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

Warm Autoimmune Hemolytic Anemia (wAIHA)

The purpose of this study is to evaluate efficacy and safety of ianalumab compared to placebo in patients with warm autoimmune hemolytic anemia, who failed at least one line of treatment.

Начало: 30.12.2022 Край: 19.12.2028 Възраст: 18–100 г. Лечение

Argentina, Australia, China +13 Novartis Pharmaceuticals NCT05648968

Активно (без набиране) Фаза 3

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

Atherosclerotic Cardiovascular Disease

The primary objective of this trial is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).

Начало: 14.12.2022 Край: 31.03.2028 Възраст: 18–85 г. Лечение

Argentina, Australia, Belgium +28 Amgen NCT05581303

Активно (без набиране) Фаза 2/3

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

The purpose of this study is to evaluate the safety and efficacy of oral azacitidine in participants with low to intermediate International Prognostic Scoring System Revised (IPSS-R) myelodysplastic syndrome (MDS).

Начало: 14.12.2022 Край: 31.07.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Canada +13 Bristol-Myers Squibb NCT05469737

Активно (без набиране) Фаза 1/2

Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients

Hereditary Angioedema

The first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-324 in healthy volunteers (HV) and in patients with Hereditary Angioedema (HAE).

Начало: 14.12.2022 Край: 30.12.2027 Възраст: 18–55 г. Лечение

Australia ADARx Pharmaceuticals, Inc. NCT05691361

Активно (без набиране) Фаза 3

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Non-small Cell Lung Cancer

This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins mutation, who are newly diagnosed or have not received prior systemic therapy in advanced stage. Primary objective of this study is to assess the efficacy of DZD9008 versus platinum-based doublet chemotherapy using by BICR-assessed PFS per RECIST 1.1 as primary endpoint. Approximately 320 participants are estimated to be randomized into the study. Participants enrolled will be randomized to DZD9008 or platinum-based doublet chemotherapy in a 1:1 manner, stratified by baseline brain metastasis (with/without).

Начало: 13.12.2022 Край: 31.10.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +12 Dizal Pharmaceuticals NCT05668988

Активно (без набиране) Фаза 3

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

Severe Hypertriglyceridemia

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

Начало: 13.12.2022 Край: 01.03.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +28 Ionis Pharmaceuticals, Inc. NCT05681351

Активно (без набиране) Фаза 3

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Chronic Spontaneous Urticaria

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 core studies. This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.

Начало: 09.12.2022 Край: 02.08.2027 Възраст: 18–100 г. Лечение

Argentina, Australia, Brazil +26 Novartis Pharmaceuticals NCT05513001

Активно (без набиране) Фаза 3

A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia

Friedreich Ataxia

The primary objective of this study is to assess the long-term safety of vatiquinone in participants with Friedreich ataxia (FA) previously exposed to vatiquinone.

Начало: 08.12.2022 Край: 31.12.2027 Лечение

Australia, Brazil, Canada +6 PTC Therapeutics NCT05515536

Активно (без набиране) Фаза 3

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

Breast Cancer

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.

Начало: 08.12.2022 Край: 31.12.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +19 Celcuity Inc NCT05501886

Активно (без набиране) Фаза 3

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

Chronic Hepatitis B Hepatitis B, Chronic

This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and the durability of hepatitis B virus surface antigen (HBsAg) suppression observed with bepirovirsen for 24 weeks (with loading doses) as compared to the placebo arm. This study will have 4 stages: a) Double-blind treatment (bepirovirsen or placebo) for 24 weeks. b) Nucleos(t)ide analogue (NA) treatment for 24 weeks. c) NA cessation stage OR Continue NA for 24 weeks. d) Durability of response and follow up for further 24 weeks for participants who stopped NA treatment at Week 48. The arms will be stratified based on HBsAg level (HBsAg greater than or equal to \[≥\] 100 international unit per milliliter \[IU/mL\] to less than or equal \[≤\]1000 IU/mL or greater than \[\>\] 1000 IU/mL to ≤3000 IU/mL) at screening. The total duration of the study, including screening (up to 60 days), the double-blind treatment stage (24 weeks), the On NA only stage (24 weeks), and the NA cessation and durability stages (48 weeks) is up to approximately 104 weeks at maximum for each participant.

Начало: 06.12.2022 Край: 29.04.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +24 GlaxoSmithKline NCT05630820

Активно (без набиране) Фаза 3

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Cough Refractory Chronic Cough

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Начало: 05.12.2022 Край: 17.03.2027 Възраст: 18–80 г. Лечение

Australia, Canada, China +10 Bellus Health Inc. - a GSK company NCT05600777

Активно (без набиране) Фаза 1

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

Advanced Solid Tumors

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-706 as a monotherapy and in combination with budigalimab, carboplatin, or cisplatin. ABBV-706 is an investigational drug being developed for the treatment of small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors and high-grade neuroendocrine carcinomas (NECs). There are multiple treatment arms in this study. Participants will either receive ABBV-706 as a single agent or in combination with budigalimab (another investigational drug), carboplatin or cisplatin at different doses. Approximately 350 adult participants will be enrolled in the study across sites worldwide. In part 1 (dose escalation), ABBV-706 will be intravenously infused in escalating doses as a monotherapy until the maximum tolerated dose (MTD) is determined in participants with SCLC, high-grade CNS tumors, and high-grade NECs. In part 2, multiple doses will be selected from Part 1 and SCLC participants will be assigned to one of these doses in a randomized fashion to determine the recommended Phase 2 dose. In Part 3a, participants with SCLC or NECs will receive ABBV-706 in combination with budigalimab intravenously every 3 weeks. In Part 3b participants with SCLC or NECs will receive ABBV-706 in combination with either carboplatin or cisplatin intravenously. In Part 4a, participants with CNS tumors will receive ABBV-706 intravenously at a dose determined from Part 1. In Part 4b, participants with NECs will receive ABBV-706 intravenously at a dose selected from Part 1. The estimated duration of the study is up to 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

Начало: 05.12.2022 Край: 01.06.2026 Възраст: от 18 г. Лечение

Australia, China, France +7 AbbVie NCT05599984

Активно (без набиране) Фаза 3

Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

HIV Organ Transplantation Lymphoma, Non-Hodgkin Chronic Lymphocytic Leukemia +2

Despite the greater risk of adverse COVID-19 outcomes, antibody and cell-mediated immune responses to COVID-19 vaccines vary amongst immunocompromised (IC) people and are poorly defined. IC hosts were largely excluded from the COVID-19 vaccine registration trials, though many countries recommend additional and booster doses of vaccination in this group. BOOST-IC is an adaptive randomised clinical trial (RCT) to assess the immunogenicity and safety of additional COVID-19 vaccine doses in immunocompromised (IC) people, including people with HIV, solid organ transplants (SOT) recipients or those with haematological malignancies. Briefly, the study aims to generate high-quality evidence on the immunogenicity and safety of alternative COVID-19 booster strategies against SARS-CoV-2 for IC people in Australia.

Начало: 01.12.2022 Край: 31.12.2026 Възраст: от 16 г. Лечение

Australia Monash University NCT05556720

Активно (без набиране) Фаза 1/2

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

Locally Advanced Urothelial Carcinoma Metastatic Urothelial Carcinoma Solid Tumor Urothelial Carcinoma +10

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic urothelial carcinoma of the bladder and urinary tract and other advanced solid tumors.

Начало: 22.11.2022 Край: 01.06.2027 Възраст: от 18 г. Лечение

Australia, France, Spain +1 Tyra Biosciences, Inc NCT05544552

Активно (без набиране)

PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

Benign Prostatic Hyperplasia Localized Prostate Cancer

The goal of this clinical trial is to assess the performance and safety of the AQUABEAM Robotic System for the resection and removal of prostate tissue in patients experiencing lower urinary tract symptoms (LUTS) and are diagnosed with localized prostate cancer. Participants will go through baseline and follow up assessments up to 12 months.

Начало: 22.11.2022 Край: 01.03.2027 Възраст: до 80 г. Лечение

Hong Kong, Lebanon, New Zealand +1 PROCEPT BioRobotics NCT06051942

Активно (без набиране) Фаза 2

A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

Inflammatory Bowel Diseases Colitis, Ulcerative

This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC).

Начало: 21.11.2022 Край: 01.08.2026 Възраст: 18–85 г. Лечение

Australia, Bulgaria, Czechia +17 Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of NCT05611671

Активно (без набиране)

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

Neovascular Age-related Macular Degeneration Diabetic Macular Edema Retinal Vein Occlusion Branch Retinal Vein Occlusion +2

The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products in approved retinal indications (Faricimab for neovascular age-related macular degeneration \[nAMD\], diabetic macular edema \[DME\], and retinal vein occlusion; Port Delivery System with Ranibizumab for nAMD) in routine clinical practice. This study will not provide or make recommendations on use of any products including Roche products; treatment decisions will be determined by the treating physician and must be made independently to the decision to participate in this study. Participation in this study will not change or influence a patient's standard of care in any way.

Начало: 21.11.2022 Край: 30.11.2027 Възраст: от 18 г.

Argentina, Australia, Bulgaria +24 Hoffmann-La Roche NCT05476926

Активно (без набиране) Фаза 3

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

Advanced Upper Gastrointestinal Tract Adenocarcinoma

This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) monoclonal antibody domvanalimab, the anti programmed cell death protein 1 (PD-1) monoclonal antibody zimberelimab, and multiagent chemotherapy versus the anti PD-1 monoclonal antibody nivolumab and multiagent chemotherapy in the first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.

Начало: 21.11.2022 Край: 01.06.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +25 Arcus Biosciences, Inc. NCT05568095

Активно (без набиране) Фаза 3

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodysplasia Ossificans Progressiva

This study is researching an experimental drug called garetosmab. The study is focused on adult patients with fibrodysplasia ossificans progressiva (FOP). The aim of the study is to see how safe and effective the study drug is in patients with FOP. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Начало: 21.11.2022 Край: 27.02.2029 Възраст: от 18 г. Лечение

Australia, Brazil, Chile +15 Regeneron Pharmaceuticals NCT05394116

1 … 113 114 115 116 117 … 154